Premium
High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study
Author(s) -
Preisler H. D.,
Raza A.,
Barcos M.,
Azarnia N.,
Larson R.,
Browman G.,
Walker I.,
Grunwald H.,
D'Arrigo P.,
Stein A.,
Bloom M.,
Goldberg J.,
Gottlieb A.,
Bennett J.,
Kirshner J.,
Priore R.
Publication year - 1986
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830230207
Subject(s) - myelofibrosis , medicine , cytosine , leukemia , complete remission , toxicity , myeloproliferative disorders , gastroenterology , preleukemia , oncology , chemotherapy , bone marrow , biology , genetics , dna
Fifteen patients with myelodysplastic/myeloproliferative disorders were treated with high‐dose cytosine arabinoside therapy. While severe toxicity was produced in every patient, only two of the 15 patients entered complete remission and two achieved partial remission status. The therapeutic responses were confined to patients who had severe myelofibrosis of apparently recent onset.